Another unexpected discovery was that IT 2141-V11 not only was safe but appear to trigger tertiary lymphoid structures (TLS) formation. These findings not only supports intratumoral administration as a safe approach but also the most effective way to promote optimal immune activation/interactions

CD40 agonists have shown promise but failed due to toxicity and weak activity. We previously showed that 2141-V11, Fc-engineered for increased FcγRIIB binding, leads to superior antitumor activity and reduced toxicity when given intratumorally in preclinical models, paving the way for this trial.

Join us at #CICON25, September 10-12 in Utrecht. This is an exciting venue to explore how novel insights in immuno-oncology can translate into life-changing outcomes! Review the program, submit an abstract and register today: bit.ly/4cjiDJ4 cancerimmunotherapyconference.org

Thrilled to present at @theaacr.bsky.social annual meeting at the Clinical Trials Plenary Session on Biologics and T-cell Engagers! See you there to present some exciting data on our Fc-engineered CD40 agonistic antibody #AACR25

Science not silence

Thrilled to present our for on this co-“stimulating” session organized by @sitcancer.bsky.social Join us this Thursday! Moderated by leaders in the field and presentations of exciting progress in IO for cancer. sitcancer.org/education/we...